OVARIAN CANCER CLINICAL ADVISORY BOARD

The members of the Cognos Therapeutics, Inc. (Cognos) Ovarian Cancer Clinical Advisory Board were brought together because of their expertise and profound insights into the pathology, treatment, and remediation of one of the top cancer risks facing women today; ovarian cancer. In the U.S. alone it is anticipated that ovarian cancer will claim the lives of over 15,000 women in 2017,

Cognos is dedicated to being a key player in providing effective new diagnostic and disease remediation tools in the battle against this pervasive killer. The Cognos Ovarian Cancer Clinical Advisory Board provides advice from a clinical point of view about the design, context, and content of Cognos’ ongoing research and product development. In addition, the Ovarian Cancer Clinical Advisory Board advises Cognos on project proposals as it relates to internal and external funding efforts by the company. Finally the Ovarian Cancer Clinical Advisory Board informs Cognos about relevant new clinical insights and developments.

Dr. Hanni Gabra,

MD, PHD, FRCP

CHAIRMAN